Blood protein study in non-intensive chemotherapy for AML and MDS
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS), or chronic myelomonocytic leukemia (CMML), either for the first time or after a relapse.
- You are currently being treated with a hypomethylating agent (like azacitidine or decitabine), either alone or combined with venetoclax or another drug.
- You agree to sign a consent form to allow researchers to collect and study your blood samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how a certain biological pathway (called BMP) affects the progression of blood cancers like MDS and AML. By understanding this, doctors hope to find better ways to predict or treat these conditions.
This study looks at how blood and clotting are affected in people newly diagnosed with acute myeloid leukemia (AML) who receive a common intensive chemotherapy combination (idarubicin and cytarabine). The goal is to better understand blood-related side effects and improve care.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.